Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a pseudogene, a non-functional genomic DNA sequence that resembles functional guanine nucleotide-binding protein family genes (such as GNAQ, GNG11, etc.) but typically does not encode a functional protein due to inactivating mutations[2][4]. Pseudogenes can have biological significance in that their transcripts may regulate their parental genes through mechanisms like microRNA sponging—acting as "decoys" for microRNAs, thereby altering the levels of their protein-coding counterparts[1][4]. Some pseudogene RNAs may also be processed into endogenous small interfering RNAs that modulate gene expression, though most are not directly translated into protein[1][2][4]. In some cases, pseudogenes show tissue-specific or disease-specific expression—potentially influencing cancer progression or cellular homeostasis, but their roles are typically *regulatory* and indirect[1][2]. Guanine nucleotide binding protein pseudogenes are not considered receptors, enzymes, or direct therapeutic targets; they belong to the "Pseudogene" molecular classification, and current evidence does not support direct drug interactions, biomarker utility, nor safety concerns associated with targeting them[1][2][4]. Is something wrong with this target? Yes, this target is not a protein-coding gene and is not considered a canonical drug target (e.g., receptor, enzyme, etc.). It is classified as a pseudogene, which renders it unsuitable for direct therapeutic targeting. Structured data for therapeutic drug development should focus on functional proteins rather than pseudogenes[2][4]. Key summary points: - ENSG00000254719 maps to a guanine nucleotide binding protein pseudogene, not a canonical or actionable target. - Its most accurate classification is "Pseudogene," not "Receptor," "Enzyme," or similar categories. - It is unlikely to have common drug interactions, mechanisms of action for drug targeting, safety concerns, or use as biomarkers. - Any gene regulatory functions are indirect and arise primarily through noncoding RNA mechanisms, not through protein action[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanine nucleotide binding protein pseudogene.